[Confidential Treatment Requested. Confidential Portions of this Agreement
have been redacted and have been separately filed with the Commission.]
EXHIBIT 10.2
EXECUTION COPY
FIRST AMENDMENT OF COLLABORATIVE RESEARCH
AND DEVELOPMENT AND LICENSE AGREEMENT
This First Amendment of Collaborative Research and Development and License
Agreement is made and effective as of September 25, 2000, by and among Becton,
▇▇▇▇▇▇▇▇▇ and Company, a New Jersey corporation through its BD Biosciences
Division, having a place of business at ▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
(hereinafter "Becton"), Nanogen, Inc., a Delaware corporation having its
principal office and place of business at ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇,
▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ (hereinafter "Nanogen") and The Nanogen/Becton ▇▇▇▇▇▇▇▇▇
Partnership, a Delaware general partnership, having a place of business at ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ (hereinafter "the
Partnership").
WHEREAS, Becton, Nanogen and the Partnership are parties to a certain
Collaborative Research and Development and License Agreement (hereinafter
"CRDA") effective 1 October 1997; and
WHEREAS, the parties desire to amend certain provisions of the CRDA.
NOW, THEREFORE, for good and valuable consideration, the parties hereby
agree as follows:
1. Paragraph 1.6 is hereby amended by adding a period after the
parenthesis after the word "parasites" and by deleting the remainder
of that sentence and the following sentence in that paragraph.
2. Paragraph 1.8 is hereby amended to read in its entirety as follows:
"Master Agreement" shall mean that certain Master Agreement dated as
of October 1, 1997, as amended as of September 25, 2000, between
Becton and Nanogen.
3. Paragraph 1.13 is hereby amended to read in its entirety as follows:
"Partnership Agreement" shall mean that certain General Partnership
Agreement dated asof October 1, 1997, as amended as of September 25,
2000, between the Partners.
4. The licenses respectively granted by Becton pursuant to Paragraphs
6.1(a)(i) and (ii) and by Nanogen pursuant to Paragraphs 6.1(b)(i) and
(ii) are hereby deemed terminated and of no further force and effect.
5. New Paragraph 6.1(d) is hereby added as follows:
(d) The Partnership hereby: (i) grants to Becton a worldwide,
royalty-free, exclusive license in and to Program Inventions listed in
Exhibit A hereto
2
(hereinafter "Product Commercialization Rights") to make, have made,
use, offer to sell, sell and import Products in the Field, for the
sole purpose of hereby granting to Nanogen, a worldwide,
royalty-bearing, exclusive sublicense, with a limited right to grant
further sublicenses, in and to Product Commercialization Rights to
make, have made, use, offer to sell, sell and import Products in the
Field by means of a certain Partnership Product Commercialization
License Agreement to be executed concurrently herewith; (ii) assigns
and transfers to Nanogen all right, title and interest in and to
Program Inventions listed in Exhibit B hereto by means of a certain
Partnership to Nanogen Assignment Agreement to be executed
concurrently herewith; (iii) assigns and transfers to Becton all
right, title and interest in and to Program Inventions listed in
Exhibit C hereto by means of a certain Partnership to Becton
Assignment Agreement to be executed concurrently herewith; and (iv)
assigns and transfers to Nanogen and Becton jointly all right, title
and interest in and to Program Inventions listed in Exhibit D hereto
by means of a certain Partnership to Nanogen and Becton Assignment
Agreement to be executed concurrently herewith.
6. Paragraph 6.6 is hereby deemed deleted in its entirety.
7. Paragraph 7.1 is hereby amended by adding the words "and Paragraph
6.1(d)" after the words "Paragraph 6.1(c)" in the first sentence.
8. In Paragraph 12, the Notice address for Becton is hereby amended to
read as follows (the address for copies remaining unchanged):
BD Biosciences
▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attn: Vice President, Licensing and Patents
and the facsimile number for Nanogen is hereby amended to read "858-
410-4949" instead of "▇▇▇ ▇▇▇-▇▇▇▇".
Except with respect to the foregoing amendments, all other provisions of
the CRDA remain unmodified and in full force and effect.
[SIGNATURES APPEAR ON NEXT PAGE]
3
IN WITNESS WHEREOF, the parties have executed this First Amendment of
Collaborative Research and Development and License Agreement through duly
authorized representatives on the dates set forth below, effective as of the
date first written above.
NANOGEN, INC. BECTON, ▇▇▇▇▇▇▇▇▇ AND COMPANY
THROUGH ITS BD BIOSCIENCES DIVISION
By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------ ----------------------------------
Authorized Signature Authorized Signature
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ SENIOR VICE PRESIDENT
CHAIRMAN AND CEO TECHNOLOGY, STRATEGY & DEVELOPMENT
------------------------------ ----------------------------------
Name and Title Name and Title
Date: 9/27/00 Date: September 28, 2000
------------------------------ ----------------------------------
THE NANOGEN/BECTON ▇▇▇▇▇▇▇▇▇ PARTNERSHIP,
A DELAWARE GENERAL PARTNERSHIP
NANOGEN VENTURE LLC BECTON ▇▇▇▇▇▇▇▇▇ VENTURE LLC
GENERAL PARTNER GENERAL PARTNER
By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------ ----------------------------------
Authorized Signature Authorized Signature
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ SENIOR VICE PRESIDENT
CHAIRMAND & CEO TECHNOLOGY, STRATEGY & DEVELOPMENT
------------------------------ ----------------------------------
Name and Title Name and Title
Date: 9-27-00 Date: September 28, 2000
------------------------------ ----------------------------------
4
APPENDIX A
PRODUCT COMMERCIALIZATION RIGHTS
1. *************************************************************************
*************************************************************************
*************************************************************************
2. *************************************************************************
*************************************************************************
*************************************************************************
3. *************************************************************************
*************************************************************************
*************************************************************************
4. *************************************************************************
*************************************************************************
*************************************************************************
*************************************************************************
5. *************************************************************************
*************************************************************************
*************************************************************************
6. U. S. Patent No. 6,066,461, entitled "Amplification and Detection of
Campylobacter jejuni and Campylobacter coli"
7. *************************************************************************
*************************************************************************
8. U. S. Patent No. 6,060,252, entitled "Amplification and Detection of
Shigella spp. and Enteroinvasive Strains of Escherichia coli"
9. *************************************************************************
*************************************************************************
-------------------
*** Confidential material redacted and separately filed with the Commission.
5
10. U. S. Patent No. 6,043,041, entitled "Amplification and Detection of
Shiga-like Toxin II Producing Organisms"
11. *************************************************************************
*************************************************************************
-------------------
*** Confidential material redacted and separately filed with the Commission.
6
APPENDIX B
PROGRAM INVENTIONS ASSIGNED TO NANOGEN
1. ***********************************************************************
***********************************************************************
2. ***********************************************************************
***********************************************************************
3. ***********************************************************************
***********************************************************************
-------------------
*** Confidential material redacted and separately filed with the Commission.
7
APPENDIX C
PROGRAM INVENTIONS ASSIGNED TO ▇▇▇▇▇▇
▇. ***********************************************************************
***********************************************************************
2. ***********************************************************************
***********************************************************************
-------------------
*** Confidential material redacted and separately filed with the Commission.
8
Appendix D
PROGRAM INVENTIONS ASSIGNED TO NANOGEN AND BECTON JOINTLY
1. ***********************************************************************
***********************************************************************
2. ***********************************************************************
***********************************************************************
3. ***********************************************************************
***********************************************************************
***********************************************************************
4. ***********************************************************************
-------------------
*** Confidential material redacted and separately filed with the Commission.